Literature DB >> 28362182

Pediatric spinal cord astrocytomas: a retrospective study of 348 patients from the SEER database.

Andrew S Luksik1, Tomas Garzon-Muvdi1, Wuyang Yang1, Judy Huang1, George I Jallo1,2.   

Abstract

OBJECTIVE Intramedullary spinal cord tumors comprise 1%-10% of all childhood central nervous system neoplasms, with astrocytomas representing the most common subtype. Due to their rarity and poor prognosis, large population-based studies are needed to assess the epidemiology and survival risk factors associated with these tumors in the hope of improving outcome. The authors undertook this retrospective study to explore factors that may influence survival in pediatric patients with spinal cord astrocytomas. METHODS Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a prospective cancer registry, the authors retrospectively assessed survival in histologically confirmed, primary spinal cord astrocytomas in patients 21 years of age and younger. Survival was described with Kaplan-Meyer curves, and a multivariate regression analysis was used to assess the association of several variables with survival while controlling for confounding variables. RESULTS This analysis of 348 cases showed that age (hazard ratio [HR] 1.05, 95% CI 1.01-1.09, p = 0.017), nonwhite race (HR 1.74, 95% CI 1.11-2.74, p = 0.014), high-grade tumor status (HR 14.67, 95% CI 6.69-32.14, p < 0.001), distant or invasive extension of the tumor (HR 2.37, 95% CI 1.02-5.49, p = 0.046), and radiation therapy (HR 3.74, 95% CI 2.18-6.41, p < 0.001) were associated with decreased survival. Partial resection (HR 0.37, 95% CI 0.16-0.83, p = 0.017) and gross-total resection (HR 0.39, 95% CI 0.16-0.95, p = 0.039) were associated with improved survival. CONCLUSIONS Younger age appears to be protective, while high-grade tumors have a much worse prognosis. Early diagnosis and access to surgery appears necessary for improving outcomes, while radiation therapy has an unclear role. There is still much to learn about this disease in the hope of curing children with the misfortune of having one of these rare tumors.

Entities:  

Keywords:  AFT = accelerated failure time; HR = hazard ratio; ICD-O-3 = International Classification of Diseases for Oncology, Third Edition; SEER = Surveillance, Epidemiology, and End Results; WHO = World Health Organization; astrocytoma; oncology; pediatric; spinal cord; spine

Mesh:

Year:  2017        PMID: 28362182     DOI: 10.3171/2017.1.PEDS16528

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  9 in total

Review 1.  Primary and metastatic glioblastoma of the spine in the pediatric population: a systematic review.

Authors:  Runze Yang; Albert M Isaacs; Magalie Cadieux; Tomas J Hirmer; Travis S CreveCoeur; Andrew P Lapointe; Michael Opoku-Darko; Zahra Premji; Jay Riva-Cambrin; Clare N Gallagher
Journal:  Childs Nerv Syst       Date:  2021-03-06       Impact factor: 1.475

2.  Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas.

Authors:  Andrew M Hersh; Albert Antar; Zach Pennington; Nafi Aygun; Jaimin Patel; Earl Goldsborough; Jose L Porras; Aladine A Elsamadicy; Daniel Lubelski; Jean-Paul Wolinsky; George I Jallo; Ziya L Gokaslan; Sheng-Fu Larry Lo; Daniel M Sciubba
Journal:  J Neurooncol       Date:  2022-05-11       Impact factor: 4.130

3.  High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group.

Authors:  Thomas Perwein; Martin Benesch; Daniela Kandels; Torsten Pietsch; René Schmidt; Franz Quehenberger; Brigitte Bison; Monika Warmuth-Metz; Beate Timmermann; Jürgen Krauss; Ulrich-Wilhelm Thomale; Rolf-Dieter Kortmann; Pablo Hernáiz Driever; Astrid Katharina Gnekow
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

4.  Pediatric spinal cord gliomas-low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?

Authors:  Sameer Farouk Sait; Matthias A Karajannis
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

Review 5.  An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female.

Authors:  Benjamin J Delgado; Leila Moosavi; Ericka Rangel; William Stull; Rahul Dev Polineni; Joseph Chen; Everardo Cobos
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

6.  Multifocal spinal glioblastoma and leptomeningeal carcinomatosis in an elderly male with hydrocephalus and myelopathy.

Authors:  George W Koutsouras; Annelle Amsellem; Timothy Richardson; Harish Babu
Journal:  Surg Neurol Int       Date:  2021-12-08

Review 7.  Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics.

Authors:  Andrew M Hersh; George I Jallo; Nir Shimony
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

8.  Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma.

Authors:  Narihito Nagoshi; Osahiko Tsuji; Satoshi Suzuki; Satoshi Nori; Mitsuru Yagi; Eijiro Okada; Hajime Okita; Nobuyuki Fujita; Ken Ishii; Morio Matsumoto; Masaya Nakamura; Kota Watanabe
Journal:  Spinal Cord       Date:  2021-07-26       Impact factor: 2.772

9.  Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.

Authors:  Sheng Yang; Xun Yang; Huiwen Wang; Yuelin Gu; Jingjing Feng; Xianfeng Qin; Chaobo Feng; Yufeng Li; Lijun Liu; Guoxin Fan; Xiang Liao; Shisheng He
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.